



01-05-06

IFW

EXPRESS MAIL NO.: EV452776878US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zeldis et al.

Confirmation No.: 2389

Application No: 10/693,722

Group Art Unit: 1614

Filed: October 23, 2003

Examiner: To Be Assigned

For: METHODS OF USING AND  
COMPOSITIONS COMPRISING  
SELECTIVE CYTOKINE INHIBITORY  
DRUGS FOR TREATMENT,  
MODIFICATION AND MANAGEMENT  
OF PAIN

Jones Day Docket No.: 9516-078-999  
(CAM No.: 501872-999077)

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicants hereby direct the Examiner's attention to references **A122** and **C04** listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." This Information Disclosure Statement supplements the Information Disclosure Statements filed on July 26, 2004 and March 1, 2005.

References submitted in this Supplemental Information Disclosure Statement were cited in an International Search Report dated June 7, 2005, in a corresponding PCT application.


Copies of reference **C04** and the International Search Report are provided herewith. A copy of Reference **A122**, which is a United States patent publication, is not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. **503013**.

Respectfully submitted,

Date: January 3, 2006

	(Reg. No.)
Yeahsil Moon	52,042
For: Anthony M. Insogna	35,203
<b>JONES DAY</b>	
222 East 41 <sup>st</sup> Street	
New York, New York 10017	
(212) 326-3939	

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-078-999

APPLICATION NO.

10/693,722

APPLICANT

Zeldis et al.

FILING DATE

October 23, 2003

GROUP

1614

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A122	2003/0087962	05/08/2003	Demopulos et al.			
	A123						
	A124						
	A125						
	A126						
	A127						
	A128						
	A129						
	A130						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

**OTHER REFERENCES** (Including Author, Title, Date, Pertinent Pages, Etc.)

	C04	Wagner et al., "Endoneurial injection of TNF-alpha produces neuropathic pain behaviors," Neuroreport, 1996 Nov 25;7(18):2897-901

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.